ArticleThe Biochemical journal2006
Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody.
Article in The Biochemical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Physiological IgM class catalytic antibodies selective for transthyretin amyloid.The Journal of biological chemistry · 2014Trial
- Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.The Journal of biological chemistry · 2012Trial
- Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies.Scientific reports · 2024Article
- Crystal structures of the human IgD Fab reveal insights into CMolecular immunology · 2023Article
- Article
- Article
- Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.International journal of molecular sciences · 2022Article
- A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain.Scientific reports · 2022Article
- Cryomicroscopy reveals the structural basis for a flexible hinge motion in the immunoglobulin M pentamer.Nature communications · 2022Article
- Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule.RSC chemical biology · 2021Article
- A new algorithm to convert a normal antibody into the corresponding catalytic antibody.Science advances · 2020Article
- New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β-amyloid molecule along with the peptidase activity.FASEB bioAdvances · 2019Article
- Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.Molecular neurobiology · 2015Article
- Metal-dependent amyloid β-degrading catalytic antibody construct.Journal of biotechnology · 2014Article
- Constant domain-regulated antibody catalysis.The Journal of biological chemistry · 2012Article
- A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody.PloS one · 2009Article
- Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.The Journal of biological chemistry · 2009Article
- Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.The Journal of biological chemistry · 2008Article
- Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.The Journal of biological chemistry · 2008Article
- Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.Autoimmunity reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The 2.6 A (1 A=0.1 nm) resolution structure has been determined for the glycosylated Fab (fragment antigen binding) of an IgM (Yvo) obtained from a subject with Waldenström's macroglobulinaemia. Dynamic light scattering was used to estimate the gel point and monitor the formation of an ordered hydroscopic gel of Yvo IgM upon cooling. If a cryoglobulin forms gels in peripheral tissues and organs, the associated swelling and damage to microvasculature can result in considerable morbidity and mortality. The three-dimensional structure of the branched N-linked oligosaccharide associated with the CH1 domain (first constant domain of heavy chain) is reported. The carbohydrate may act to shield part of the lateral surface of the CH1 domain and crowd the junction between the CH1 and CH2 domains, thereby limiting the segmental flexibility of the Fab arms in intact Yvo IgM, especially at low temperatures. Recently, Yvo IgM was shown to have the properties of a naturally occurring proteolytic antibody [Paul, Karle, Planque, Taguchi, Salas, Nishiyama, Handy, Hunter, Edmundson and Hanson (2004) J. Biol. Chem. 279, 39611-39619; Planque, Bangale, Song, Karle, Taguchi, Poindexter, Bick, Edmundson, Nishiyama and Paul (2004) J. Biol Chem. 279, 14024-14032]. The Yvo protein displayed the ability to cleave, by a nucleophilic mechanism, the amide bonds of a variety of serine protease substrates and the gp120 coat protein of HIV. An atypical serine, arginine and glutamate motif is located in the middle of the Yvo antigen-binding site and displays an overall geometry that mimics the classical serine, histidine and aspartate catalytic triad of serine proteases. Our present findings indicate that pre-existing or natural antibodies can utilize at least one novel strategy for the cleavage of peptide bonds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.